An Italian scientist was awarded $20,000 for research that may help pave the way for a TDP-43 antibody-based treatment for amyotrophic lateral sclerosis (ALS). The annual Paulo Gontijo Award from the Brazilian Paulo Gontijo Institute was granted to Silvia Tozzi, PhD, for her research, titled “Monoclonal full-length antibody…

A Lief Cares initiative, under its partnership with AxeALS, raised nearly $8,000 for the amyotrophic lateral sclerosis (ALS) community and is providing patients with specially formulated nutritional supplements. Lief Cares is the nonprofit donation program of the California-based formulation and product developer and dietary supplement manufacturer Lief Labs. Through…

Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral sclerosis (ALS). Prilenia’s oral therapy pridopidine was selected as the trial’s fourth regimen (NCT04615923), with…

Amylyx Pharmaceuticals has filed an application with the European Medicines Agency seeking the approval of its lead candidate AMX0035 as a treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. The marketing authorization request follows similar submissions to Health Canada and…

A recent tweet by an Australian amyotrophic lateral sclerosis (ALS) patient using an implantable brain computer interface called Stentrode is said to be the first time a message has been posted on social media with the help of such technology. By using this brain computer interface, developed by…

An investigational antisense oligonucleotide (ASO) molecule that works by increasing the production of Stathmin-2 protein effectively reversed a number of neurodegenerative processes in lab-grown motor neurons, the cells that are damaged in amyotrophic lateral sclerosis (ALS), a study found. The rescue occurred even in the absence of TDP-43, a…

The U.S. Food and Drug Administration (FDA) has accepted for review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The new drug application (NDA) also was granted priority review by the regulatory agency, which reduces review time from the standard…

ALS News Today brought you daily coverage of the latest scientific breakthroughs and clinical research related to amyotrophic lateral sclerosis (ALS) throughout 2021. We look forward to continuing to report for the ALS community in 2022. Here are the 10 most-read ALS news articles of the last year, with…

Amyotrophic lateral sclerosis (ALS) patients who completed the expanded access protocol (EAP) for NurOwn may soon be eligible for three additional doses of the cell-based therapy, BrainStorm Cell Therapeutics reported. EAPs, also known as compassionate use programs, are intended to make investigational therapies available outside of a clinical trial…

A new partnership between Target ALS and the Alzheimer’s Drug Discovery Foundation (ADDF) will help facilitate biomarker research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and frontotemporal dementia (FTD). Identifying and validating appropriate biomarkers can help clinicians diagnose these diseases earlier, reliably track…